Redefining Lower-Risk MDS: Upfront Optimization & Long-Term Sequencing

Amer Zeidan, MBBS, MD, discussed when to start luspatercept at the full 1.75 mg/kg dose in lower-risk MDS based on the MAXILUS trial.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discuss how long-term COMMANDS data support the use of luspatercept.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed using IPSS-M criteria to detect hidden high-risk biology in lower-risk MDS.

Imetelstat may be considered as a frontline option for patients with a high transfusion burden, said Amer Zeidan, MBBS, MD.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.